JPRN-UMIN000008023招募中2 期
Phase II multicenter trial of neoadjuvant chemotherapy followed by radical hysterectomy and adjuvant chemotherapy by irrinotecan hydrochloride and nedaplatin for the patients with stage Ib2-IIb bulky cervical cancer (tumor diameter > 4 cm): OGSK_KCOG-G1201 - NACRAC study
The Obstetrical and Gynecological Society of Kinki District Japan and the Kansai Clinical Oncology Group0 个研究点目标入组 68 人开始时间: 2012年5月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Patients with an active or uncontrolled infection, 2. Patients with a serious complications (cardiac disease, poorly controlled diabetes mellitus, malignant hypertension and bleeding tendency), 3. Patients with other malignancies, 4. Patients with interstitial pneumonitis, 5. Patients with massive pleural effusion and/or ascites, 6. Patients with unstable angina or those who have had a myocardial infarction within the past six months, 7. Patients with medical contraindications to irrinotecan hydrochloride and nedaplatin, 8. Patients with severe diarrhea, 9. Patients with bowel obstruction, 10. Patients who are pregnant or lactating, 11. Patients with severe drug allergy, 12. Patients whose circumstances at the time of entry onto the protocol would not permit completion of study required follow-up, 13. Patients with HBsAg positivity
研究者
相似试验
已完成
2 期
Multicenter phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinomaoral squamous cell carcinomaJPRN-C000000023Chubu research group on oral cancer30
已完成
2 期
Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trialbreast cancerJPRN-UMIN000010227Kanagawa Breast Oncology Group (KBOG)40
尚未招募
2 期
Phase II multicenter study of neoadjuvant chemotherapy with XELOX for locally advanced rectal cancerJPRN-UMIN000024357Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University35
尚未招募
2 期
Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer.Invasive ductal adenocarcinomaJPRN-UMIN000028101Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine45
已完成
2 期
Phase II trial of neoadjuvant combination chemotherapy with gemcitabine and S-1 for locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000001450Faculty of Medicine, Kyoto University35